Literature DB >> 25867415

Administration of low-dose cyclosporine alone for the treatment of elderly patients with membranous nephropathy.

M X Li1, Y W Yu2, Z Y Zhang2, H D Zhao2, F L Xiao2.   

Abstract

This study aimed to investigate the effects of administration of low-dose cyclosporine A (CsA) alone and the combination of low-dose CsA and a low-dose hormone for the treatment of elderly patients with membranous nephropathy. We divided 27 patients into two groups as follows: low-dose CsA group (group A) and the group receiving a combination of a low-dose hormone and low-dose CsA (group B). The treatment and follow-up times were ≥ 6 months. We observed no difference in gender, age, serum creatinine levels, estimated glomerular filtration rate (eGFR), and 24-h urinary protein levels between the two groups before treatment; in addition, the rates of complete and partial remission were not different 6 months after treatment. The rate of complications in group B was higher than that in group A (84.6 vs 35.7%, respectively; t = 0.018). While the pretreatment eGFR of patients who achieved remission was significantly higher than that of patients who did not achieve remission, the 24-h urinary protein levels and incidence of hypertension were significantly lower than those of patients who did not achieve remission (t = 0.042, 0.035 and 0.043, respectively). The efficacy of administration of low-dose CsA alone and in combination with a low-dose hormone was similar; the efficacy was related to eGFR, urinary protein levels, and the incidence of hypertension before the treatment. The side effects of administration of CsA alone were significantly lower than those of the combination treatment.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25867415     DOI: 10.4238/2015.March.30.27

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  8 in total

Review 1.  Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.

Authors:  Thilo C von Groote; Gabrielle Williams; Eric H Au; Yizhi Chen; Anna T Mathew; Elisabeth M Hodson; David J Tunnicliffe
Journal:  Cochrane Database Syst Rev       Date:  2021-11-15

Review 2.  Efficacy of low or heavy rituximab‑based protocols and comparison with seven regimens in idiopathic membranous nephropathy: a systematic review and network meta-analysis.

Authors:  Miaomiao Chen; Xuehan Zhang; Yi Xiong; Gaosi Xu
Journal:  Int Urol Nephrol       Date:  2022-09-25       Impact factor: 2.266

Review 3.  Treatment of Idiopathic Membranous Nephropathy for Moderate or Severe Proteinuria: A Systematic Review and Network Meta-Analysis.

Authors:  Miaomiao Chen; Jiarong Liu; Yi Xiong; Gaosi Xu
Journal:  Int J Clin Pract       Date:  2022-04-23       Impact factor: 3.149

Review 4.  A Review of the Current Practice of Diagnosis and Treatment of Idiopathic Membranous Nephropathy in China.

Authors:  Lianzhong Wu; Jin Lai; Yixin Ling; Yiqin Weng; Shujuan Zhou; Siqi Wu; Songfu Jiang; Xiaokai Ding; Xin Jin; Kang Yu; Yi Chen
Journal:  Med Sci Monit       Date:  2021-02-07

5.  Immunosuppression therapy for idiopathic membranous nephropathy: systematic review with network meta-analysis.

Authors:  Bhadran Bose; Edmund Y M Chung; Regina Hong; Giovanni F M Strippoli; David W Johnson; Wen-Ling Yang; Sunil V Badve; Suetonia C Palmer
Journal:  J Nephrol       Date:  2022-02-23       Impact factor: 4.393

6.  Efficacy and safety of 12 immunosuppressive agents for idiopathic membranous nephropathy in adults: A pairwise and network meta-analysis.

Authors:  Jiarong Liu; Xiang Li; Tianlun Huang; Gaosi Xu
Journal:  Front Pharmacol       Date:  2022-07-25       Impact factor: 5.988

7.  The impact of coexisting diabetes mellitus on clinical outcomes in patients with idiopathic membranous nephropathy: a retrospective observational study.

Authors:  Zhiyong Xie; Zhilian Li; Wei Dong; Yuanhan Chen; Ruizhao Li; Yanhua Wu; Huaban Liang; Zhiming Ye; Shuangxin Liu; Wei Shi; Xinling Liang
Journal:  BMC Nephrol       Date:  2020-06-12       Impact factor: 2.388

8.  Low-dose cyclosporine in treatment of membranous nephropathy with nephrotic syndrome: effectiveness and renal safety.

Authors:  Xiaojuan Yu; Lin Ruan; Zhen Qu; Zhao Cui; Yimiao Zhang; Xin Wang; Liqiang Meng; Xiaojing Liu; Fang Wang; Ying Zhang; Gang Liu; Li Yang
Journal:  Ren Fail       Date:  2017-11       Impact factor: 2.606

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.